CHITTARANJAN ANDRADE, MD., Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029.
Indian J Psychiatry. 2000 Jul;42(3):295-301.
A double-blind, placebo-controlled study was conducted to evaluate the efficacy an ethanolic extract of Aswagandha (Withania somnifera), in patients with ICD-10 anxiety disorders. The sample comprised 39 subjects, of whom 20 received the drug and 19 received placebo. The two groups were sociodemographically and clinically similar at baseline. At 2 and 6 weeks follow-up, data from approximately 85% of patients in each group were available for analysis. Statistical trends favouring the drug were observed at both time points. At 6 weeks, significantly more patients met a priori response criteria in the drug group (88.2%) as compared with the placebo group (50%). The drug was well-tolerated and did not occasion more adverse effects than did placebo. It is concluded that this ethanolic extract of Withania somnifera has useful anxiolytic potential and merits further investigation.
一项双盲、安慰剂对照研究评估了用酒精提取的娑罗子（睡茄）在 ICD-10 焦虑障碍患者中的疗效。样本包括 39 名受试者，其中 20 名接受药物治疗，19 名接受安慰剂治疗。两组在基线时在社会人口统计学和临床方面相似。在 2 周和 6 周的随访中，每组约 85%的患者的数据可用于分析。在两个时间点都观察到了有利于药物的统计趋势。在 6 周时，与安慰剂组（50%）相比，药物组有更多的患者符合预先设定的反应标准（88.2%）。药物耐受性良好，没有比安慰剂引起更多的不良反应。结论是，这种用酒精提取的娑罗子具有有用的抗焦虑潜力，值得进一步研究。
